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Available online 1 October 2016Peripheral blood was collected from a 7-year-old male patient with an X-linked recessive mutation of Iduronate 2-
sulfatase (IDS) gene (NM_000202.7(IDS):c.182CNT) causingMPS II (OMIM309900). Peripheral bloodmononuclear
cells (PBMCs) were reprogrammed by lentiviral delivery of a self-silencing hOKSM polycistronic vector. The
pluripotency of the iPSC linewas conﬁrmed by the expression of pluripotency-associatedmarkers and in vitro spon-
taneousdifferentiation towards the 3 germ layers. The iPSC line showednormal karyotype. The cell line offers a good
platform to study MPS II pathophysiology, for drug testing, early biomarker discovery and gene therapy studies.
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Peripheral blood was collected from a 7-year-old male patient with
genetically characterized MPS II disorder diagnosed by Department of
Pediatrics, University of Pécs (Hungary). Based on the clinical symptoms
of the patient, the disorder was determined to be mild MPS II. The pa-
tient carries a pathogenic, X-linked, hemizygous mutation of the IDS
gene (NM_000202.7(IDS):c.182CNT, p.Ser61Phe). The single nucleotide
variation (SNV) results an amino acid change with deleterious effect on
the Iduronate 2-sulfatase enzyme function and to the accumulation of
glycosaminoglycans. Mutations of IDS gene have been shown to cause
MPS II disorder (Wraith et al. 2008). In the patient-derived iPSCs the
presence of thepathogenicmutationwas conﬁrmed by Sanger sequenc-
ing of the PCR product harboring the SNV (Table 1, Fig. 1A).
To generate the MPSII-4.1 iPSC line the
pRRL.PPT.SF.hOKSMco.idTomato.preFRT lentiviral vector was used,
which was shown that under certain condition is self-silencing shortly
after transduction (Voelkel et al. 2010; Warlich et al. 2011). The iPSC-
like colonies were picked 18–21 days post-transduction and one stable
line was maintained named: MPSII-4.1 whichwas expanded for further
examination.
The pluripotency of MPSII-4.1 line was conﬁrmed by alkaline phos-
phatase staining (ALP) and by immunocytochemistry staining (ICC)
for endogenous NANOG and E-CADHERIN (Fig. 1B) after silencing of
the exogenous hOKSM construct.
The in vitro spontaneous differentiation potential of the iPSC line to-
wards the three germ layers was demonstrated by the expression of ec-
todermal (βIII-TUBULIN), mesodermal (BRACHYURY) and endodermal
(GATA4) markers (Fig. 1B) using ICC.the CC BY license
Table 1
Primers used in the study.
Gene symbol Nucleotide change Protein change Fwd and Rvs primers (5′ - 3′) PCR product (bp)
IDS c.182C N T (NM_000202.7) p.Ser61Phe CCTTGGGCCTCTTAGTAACC
CTTCTGAGCACCAGGCAAG
517
464 E. Varga et al. / Stem Cell Research 17 (2016) 463–465The karyotype of theMPSII-4.1 iPSC linewas determined by Giemsa-
banding, proving normal diploid 46, XY karyotype, without any detect-
able abnormalities (Fig. 1B).Materials and methods
Experimental procedures
The chemicals were purchased from Sigma-Aldrich and all the cul-
ture reagents from Thermo Fisher Scientiﬁc, unless otherwise speciﬁed.Cell culture
All cells were cultured at 37 °C in humidiﬁed atmosphere containing
5%CO2. The iPSCswere cultured onMatrigel (BDBiosciences) inmTeSR-
1 medium (Stem Cell Technologies) following the manufacturer's
instructions.Pl
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Fig. 1. Characterization ofMPSII-4.1 iPSC line. A) Sanger sequencing of the region containing the
of the generated iPSC (4×), the iPSC line showed Alkaline Phosphatase activity (ALP) (10×) and
green), nucleuswas labelledwithDAPI (in blue). Bottom: Spontaneousdifferentiation potential
and endodermal (GATA4) germ layers (40×) (in green), the nucleus was labelled with DAPI (Reprogramming of PBMCs
PBMCs were isolated using the Vacutainer® CPT™ Cell Preparation
Tube with Sodium Heparin (BD Biosciences). PBMCs were seeded
(1 × 106 cells) in Expansion Medium (EM): QBSF-60 medium (Quality
Biological) supplemented with 50 μg/ml Ascorbic acid, 1% Pen/Strep,
50 ng/ml SCF (R&D systems), 10 ng/ml IL-3 (R&D systems), 2 U/ml
EPO (R&D systems), 40 ng/ml IGF-1 (R&D systems) and 1 μM Dexa-
methasone. Three days later the cells were transduced with
pRRL.PPT.SF.hOKSMco.idTomato.preFRT (Voelkel et al. 2010; Warlich
et al. 2011) vector using conventional lentivirus transduction at 0,2–
0,4MOI. Three days post-transduction the cells were seeded ontoMito-
mycin C treated-MEF in IMDMMEFmedium (IMDM, 10% FBS, 1% 100×
MEM Non-Essential Amino Acid Solution, 0.1 mM β-mercaptoethanol,
1% Pen/Strep) supplemented with 50 μg/ml Ascorbic acid and growth
factors applied in EM medium. From day seven post-transduction cells
were cultured in HESC medium: DMEM/F12, 20% Knockout Serum Re-
placement, 1% 100× MEM Non-Essential Amino Acid Solution, 0.1 mM
β-mercaptoethanol, 0.5% Pen/Strep, 10 ng/ml bFGF, supplementedKa
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NM_000202.7(IDS):c.182C N T SNV in the newly established iPSC line. B) Top:Morphology
was positive for pluripotency-associatedmarkers: NANOG (20×), E-CADHERIN (40×) (in
(Day14)was conﬁrmedby ICC formesodermal (BRACHYURY), ectodermal (βIII-TUBULIN)
in blue), karyogram showing normal 46 chromosomes (XY).
Table 2
Antibodies used in this study.
Manufacturer Dilution
Pluripotency markers
Mouse anti-E-Cadherin (human)
Goat anti-hNanog
Thermo Fischer Sci.
R&D Systems
1/1000
1/50
Three germ layer markers
Rabbit anti-βIII-Tubulin
Rabbit anti-BrachyuryT
Mouse anti-GATA4
Covance
Santa Cruz
Santa Cruz
1/2000
1/50
1/50
Secondary antibodies
Alexa Fluor 488 donkey anti-goat IgG
Alexa Fluor 488 donkey anti-mouse IgG
Alexa Fluor 488 donkey anti-rabbit IgG
Thermo Fischer Sci.
Thermo Fischer Sci.
Thermo Fischer Sci.
1/2000
1/2000
1/2000
465E. Varga et al. / Stem Cell Research 17 (2016) 463–465with 50 μg/ml Ascorbic acid. The appeared ES-like colonies were manu-
ally picked (Day 18–21) and cultured as iPSCs thereafter.
Alkaline phosphatase staining
Following 4% PFA ﬁxation the cells were incubatedwith ALP solution
for 30min at RT. The stained cells were observed under invertedmicro-
scope. The ALP solution consisted of 29.7 mM TRIS base and 6 mMma-
leic acid (Fluka) pH 8.5–9.0; supplemented with 0.08%MgCl2, 10.8 mM
Naphtol-As MX Phosphate and 23 μM Fast Red TR Salt.
Immunocytochemistry staining
The expression of speciﬁc pluripotency and germ layer markers
were analyzed using conventional ICC staining. The cells were ﬁxed in
4% PFA. The antibodies and applied dilutions are listed in Table 2. The
cells were observed under ﬂuorescent microscope equipped with 3D
imaging module (AxioImager system with ApoTome, Carl Zeiss) con-
trolled by AxioVision 4.8.1 Microscope software (Carl Zeiss).
Karyotyping
Cells were treated with Demecolcine solution (10 μg/ml in HBSS),
and processed with standard methods. Giemsa-banded karyotype was
performed and a minimum of 20 metaphases were analyzed. The chro-
mosomes were classiﬁed according to the International System for
Human Cytogenetic Nomenclature (ISCN).Sanger sequencing
To conﬁrm the presence of the pathogenic IDSmutation in the newly
established iPSC line PCR primers were designed to the region of inter-
est (Table 1). PCR reactions were performed using Phusion Hot Start II
High-Fidelity DNA Polymerase and MPSII-4.1 gDNA as the template.
The PCR product was puriﬁed with GenElute PCR cleanup kit and se-
quenced directly using an ABI Prism 3130xl Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA) and BigDye Terminator Cycle Sequenc-
ing v3.1 Kit (Applied Biosystems, Foster City, CA, USA).
In vitro spontaneous differentiation
Cell clumps were cultured in suspension for ﬁve days in mTeSR-1.
The formed EBswere plated on 0.1% gelatin covered cover slips in differ-
entiation medium: DMEM, 20% FBS, 1% 100× MEM Non-Essential
Amino Acid Solution, 0.1 mM β-mercaptoethanol, 1% Pen/Strep. The
cells were ﬁxed on day 14 of differentiation with 4% PFA and stained
for the 3 germ layer markers (Table 2).
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